Michael Lewitt, MD

Michael Lewitt, MD, reassures patients that topical ruxolitinib shows minimal systemic absorption despite sharing a mechanism with oral JAK inhibitors.

Michael Lewitt, MD, emphasizes adherence to twice-daily application as the primary determinant of clinical success.

Using multiple treatment modalities often achieves superior repigmentation compared with monotherapy, according to Michael Lewitt, MD.

Michael Lewitt, MD, discusses a case involving a 7-year-old girl with plaque psoriasis (PsO) affecting body surface area (BSA) and the face, emphasizing the limited pediatric treatment options and the psychological and social impact on the child; the family initially opted for topical treatments like roflumilast, but preferred a more proactive approach, transitioning to apremilast while addressing concerns about gastrointestinal adverse events and the patient’s aversion to needles.

Michael Lewitt, MD, discusses a case involving a 55-year-old man with psoriasis (PsO) and psoriatic arthritis (PsA), highlighting challenges such as treatment for sensitive areas like the palms, soles, and scalp, mild morning stiffness, and the patient’s dissatisfaction with prior topical treatments; the discussion includes systemic and topical steroid use, concerns about TNF inhibitors, the effectiveness of phototherapy on limited areas, and the potential adverse events associated with the apremilast standard dose regimen, with phototherapy considered as a rescue option for flares.

Michael Lewitt, MD, provides an overview of Case-Based Roundtable and introduces a case involving a patient with a 10-year history of plaque psoriasis (PsO) in sensitive areas, discussing the significant impact on quality of life, the patient’s aversion to needles as a new mom, and the exploration of biologic therapies as a treatment option.